
    
      The purpose of the dose escalation phase of the study is to determine the maximum tolerated
      dose/Phase 2 recommended dose of NEOD001 when given as a single agent intravenously in
      approximately 30 subjects with AL amyloidosis.

      The purpose of the expansion phase of the study is to evaluate the safety, preliminary
      efficacy and pharmacokinetics of single agent NEOD001 at the maximum tolerated dose/Phase 2
      recommended dose in approximately 25 additional evaluable subjects.
    
  